Cerevance reports Phase 3 win for experimental Parkinson’s drug

On October 7, 2026, Cerevance reported positive topline results from the Phase 3 ARISE trial of solengepras, an experimental once-daily oral Parkinson’s treatment taken alongside levodopa and other standard medications.

The 150 mg dose met the primary endpoint:
at Week 12, daily “OFF” time—when symptoms return or worsen as medication wears off—fell by 1.56 hours from baseline, versus 0.95 hours with placebo. The placebo-adjusted difference was 0.61 hours, or about 37 minutes (p=0.035).

The company also reported improvements in ON time without troublesome dyskinesia and motor activities of daily living. It highlighted potential daytime-sleepiness and quality-of-life benefits as additional findings.

Cerevance said solengepras was generally well tolerated; detailed results and further review will be important to understand the safety and size of the benefit.

The company plans to discuss the results with the U.S. FDA and determine a path toward a possible New Drug Application. Solengepras remains investigational and is not yet an approved treatment.